Stage-specific roles of microbial dysbiosis and metabolic disorders in rheumatoid arthritisMingyue Cheng, Yan Zhao, Yazhou Cui, Chaofang Zhong, Yuguo Zha, Shufeng Li, Guangxiang Cao, Mian Li, Lei Zhang, Kang Ning, Jinxiang Han
19 August 2022
Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III studyEugen Feist, Saeed Fatenejad, Sergey Grishin, Elena Korneva, Michael E Luggen, Evgeniy Nasonov, Mikhail Samsonov, Josef S Smolen, Roy M Fleischmann
15 September 2022
Age-associated B cells contribute to the pathogenesis of rheumatoid arthritis by inducing activation of fibroblast-like synoviocytes via TNF-α-mediated ERK1/2 and JAK-STAT1 pathwaysYi Qin, Ming-Long Cai, Hui-Zhi Jin, Wei Huang, Chen Zhu, Aline Bozec, Jingang Huang, Zhu Chen
27 June 2022
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trialAndra-Rodica Balanescu, Gustavo Citera, Virginia Pascual-Ramos, Deepak L Bhatt, Carol A Connell, David Gold, All-Shine Chen, Gosford Sawyerr, Andrea B Shapiro, Janet E Pope, Hendrik Schulze-Koops
3 August 2022
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaborationKim Lauper, Michele Iudici, Denis Mongin, Sytske Anne Bergstra, Denis Choquette, Catalin Codreanu, René Cordtz, Diederik De Cock, Lene Dreyer, Ori Elkayam, Ellen-Margrethe Hauge, Doreen Huschek, Kimme L Hyrich, Florenzo Iannone, Nevsun InancSee the full list of authors
15 June 2022
Tumour necrosis factor inhibitor use during pregnancy is associated with increased birth weight of rheumatoid arthritis patients’ offspringHieronymus T W Smeele, Esther Röder, Annemarie G M G J Mulders, Eric A P Steegers, Radboud J E M Dolhain
11 July 2022
Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritisAndreas Kerschbaumer, Zaïda Iasha Rivai, Josef S Smolen, Daniel Aletaha
20 June 2022
Longitudinal trajectories of fatigue in early RA: the role of inflammation, perceived disease impact and early treatment responseMichaël Doumen, Sofia Pazmino, Delphine Bertrand, Diederik De Cock, Johan Joly, René Westhovens, Patrick Verschueren
20 June 2022
Standardisation of ACPA tests: evaluation of a new candidate reference preparationLieve Van Hoovels, Lucy Studholme, Bert Vander Cruyssen, Daniela Sieghart, Carolien Bonroy, Eszter Nagy, Rille Pullerits, Sasa Čučnik, Charlotte Dahle, Ingmar Heijnen, Luca Bernasconi, Farid Benkhadra, Laura Bogaert, Stefanie Van Den Bremt, Ann Van LiedekerkeSee the full list of authors
13 June 2022
Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritisSerena Bugatti, Ludovico De Stefano, Bernardo D’Onofrio, Andrea Nicrosini, Eleonora Mauric, Michele di Lernia, Garifallia Sakellariou, Ennio Giulio Favalli, Antonio Manzo, Roberto Caporali, Carlomaurizio Montecucco
27 May 2022